Search

The article reports that Affymetrix Inc. and Stratagene Corp. has announced that they have entered into a non-exclusive strategic alliance under which Stratagene will provide Affymetrix customers with new software solutions for GeneChip data analysis. As part of this agreement, Stratagene will develop a new software package for Affymetrix, ArrayAssist Lite, which will be offered as a standard statistical analysis solution of Affymetrix gene expression microarrays. In April 2005, Affymetrix will make ArrayAssist Lite available to its existing GeneChip customers via the Internet and will also begin pre-installing the software on new GeneChip workstation desktops.

Reports on a study which found that children with asthma share a genetic profile that appear to be unique to them. Significance of the discovery to the development of treatment specifically for children who suffer from the severest form of asthma.

Reports that microarray maker Affymetrix Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2004. Net income of $27.1 million; $0.44 per basic share; $0.41 per diluted share; Net income for the year; Net cash provided by operations; Total revenue; Sale of products and wafers to Perlegen Sciences Inc.; GeneChip array; Instrument revenue; Reagent revenue.

Reports that the first high-resolution analysis of the key feature that controls the activation of genes on human chromosomes was announced by researchers from the Broad Institute of MIT and Harvard and Affymetrix Inc. Revelation of previously unknown domains of gene regulation in human chromosomes; Functional elements in the human genome; Affymetrix GeneChip DNA microarrays; Chromatin structure that packages the genome.

The article cites a study conducted by researchers at the Broad Institute of MIT and Harvard and Affymetrix Inc. published in the journal "Cell" which reveals previously unknown domains of gene regulation in human chromosomes and also suggests the existence of many functional elements in the human genome. Chromatin is a key part of the regulatory network that controls how genetic information is translated into a cell or an organism. Understanding chromatin is important because many of its components are implicated in cancer and other diseases.

The article focuses on Genelabs Technologies Inc., (GNLB) that announced that it received $1.25 million from Affymetrix Inc., for an amendment to a nonexclusive license to Genelabs' Linker-Aided DNA Amplification technology, which is known as LADA. Affymetrix had licensed the LADA technology from Genelabs in December 2002. The amendment converts the license to a fully paid up nonexclusive license and eliminates royalties and fees that were payable under the original agreement.

The article reports that Affymetrix Inc., announced that Susan Desmond-Hellmann, MD, president of product development at Genentech Inc., has been elected to the company's board of directors. In 2002, she was named to the U.S. Department of Health and Human Services Advisory Committee on Regulatory Reform. Desmond-Hellmann was named to the board of directors of the Biotechnology Industry Organization in 2001, where she now serves on the board's Executive Committee. Since 1980, she has received many honors and awards for her work in oncology and AIDS research.

The article reports that Affymetrix Inc., announced that Susan Desmond-Hellmann, president of Product Development at Genentech Inc., has been elected to the company's board of directors. In 2004, 2003, and 2001, Desmond-Hellmann was named to FORTUNE magazine's Top 50 Most Powerful Women in Business list. She is currently responsible for Genentech's Medical Affairs, Regulatory Affairs, Product Development, Development Sciences and Quality functions, as well as Business Development and Strategic Pipeline Development.

The article reports that a coalition of scientists from Asian countries announced that they are organizing a study of genetic diversity in Asian populations, the HUGO Pacific Pan-Asian SNP (single nucleotide polymorphism) Initiative, which will provide a detailed and comprehensive genetic picture of nearly half the world's population. It informs that the results from the study will be placed in a public database to help researchers better understand the scope of genetic differences between Asian populations.

The article reports that biotechnology company Affymetrix Inc. has announced the launch of 179 NimbleExpress prokaryotic array designs, providing researchers with the most comprehensive catalog offering of microarray expression products for basic microbiology and infectious disease. These arrays offer scientists an affordable tool to conduct whole-genome expression studies on a wide range of pathogenic organisms, including Bacillus anthracis, Haemophilus influenzae, and Mycobacterium tuberculosis. Affymetrix microarrays have been used in many phases of microbial research, from studying costly agricultural pathogens to studying life-threatening human diseases.

The article presents a report on new microarray test funded by NIH. Affymetrix, Inc., announced that it would be developing a biodefense microarray test that can detect hundreds of top-priority bacterial and viral biological threats, such as anthrax and plague. The new test is funded by a $2.1 million grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The new arrays under development by Affymetrix are expected to work in as little as four hours and will include: The ability to detect DNA from a deadly pathogen that has been inserted into apparently harmless bacteria; The ability to detect whether or not genes that make organisms resistant to antibiotics have been inserted into a pathogen.

The article presents information on an announcement made by Affymetrix, Inc., regarding the availability of new versions of its GeneChip E. coli and Yeast genome arrays. These arrays offer updated genomic content as well as three new strains of E. coli and one new species of yeast, expanding their utility for gene expression research. The GeneChip E. coli Genome 2.0 Array contains probe sets to detect more than 20,000 transcripts, or five times more content than the previous generation array, from multiple strains of E. coli, including the lab strain K12 and three pathogenic strains implicated in food borne illness. The array can also detect transcripts involved in antibiotic resistance.

Reports that Affymetrix Inc.'s GeneChip technology is enabling three unprecedented studies of complex brain disease as of October 2004. Details of the technology; Applications; Company background.

Reports on findings of a study which showed that identifying genetic mutations that delay puberty in a number of children may lead to better infertility treatment and birth control, conducted by Lawrence C. Layman, chief of the Medical College of Georgia Section of Reproductive Endocrinology, Infertility and Genetics.

The article reports that Genospectra Inc., has taken a nonexclusive license to a number of Affymetrix Inc.'s patents related to beads and gene-expression analysis. The license is for research use only. The patents include intellectual property in areas such as DNA and protein arrays, scanner/detector technology, and microfluidics, as well as a broadened portfolio of patents related to the use of beads to measure nucleic acids or peptide binding for genomic analysis.

The article reports that Affymetrix Inc.'s high-density oligonucleotide microarray analysis protocol that includes a linear amplification step has use in situations where RNA recovery is very low. High-density oligonucleotide microarray analysis has proven to be an excellent approach for gene expression profiling in human cancers. This technique assesses the expression of thousands of genes simultaneously, from at least 5 mcg of total RNA per sample per experiment. This total RNA requirement poses a challenge when studying small, unique clinical samples, like biopsies.

Reports on the availability in Europe of a microarray instrument system for clinical diagnostics by Affymetrix Inc.

This article focuses on Affymetrix Inc., which has announced the availability of its microarray instrument system for clinical diagnostics. The GeneChip System 3000Dx (GCS 3000Dx) is CE (Conformite Europeene) marked for in vitro diagnostic use, enabling clinical laboratories in Europe to analyze microarray diagnostics, such as the Roche AmpliChip CYP450 Test. This test, which looks for genetic variations that can affect drug efficacy and cause adverse drug reactions, is the first CE marked microarray product launched through the partnership between Roche Diagnostics and Affymetrix.